• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    There if provided a medical device () comprising a first blood bag () for collection of whole blood from a patient and a second blood bag () for separation of a platelet rich plasma (PRP) fraction, wherein: a whole blood inlet () is provided at a first end (oii) of the first blood bag () and a first blood bag outlet () is provided at a second end of the first blood bag ();. a packed cells outlet () and a plasma outlet (6) are connected to the first blood bag outlet ();. a first flexible plastic tube () connects the plasma outlet (6) to a plasma inlet (8) provided at a first end (i0i) of the second blood bag. (109). a second blood bag outlet () is provided at a second end of the second blood bag ().(Fig)
    公开号:SE1650038A1
    申请号:SE1650038
    申请日:2016-01-14
    公开日:2017-07-15
    发明作者:Ghanbari Ahmad
    申请人:Ghanbari Ahmad；
    IPC主号:
    专利说明:

    METHOD, DEVICE AND KIT FOR THE PREPARATION OF PRP TECHNICAL FIELD The present disclosure relates to the preparation of platelet-rich plasma(PRP).
    BACKGROUNDPlatelet-rich plasma (PRP) is blood plasma that has been enriched with platelets. As a concentrated source of autologous platelets, PRP contains (andreleases through degranulation) several different growth factors and other cytokines that stimulate healing, e.g. of bone and soft tissue.
    PRP was first developed in the 197os and first used in Italy in 1987 in an openheart surgery procedure. PRP therapy began gaining popularity in the mid199os. Today, PRP injections have been safely used in many fields includingwound healing, burn wound treatment, sports medicine, orthopaedics, cosmetics, faciomaxillary, gynaecology and urology.
    The efficacy of certain growth factors in healing various injuries and theconcentrations of these growth factors found within PRP are the theoreticalbasis for the use of PRP in tissue repair. The platelets collected in PRP may beactivated by the addition of thrombin and calcium chloride, which inducesthe release of the mentioned factors from alpha granules. The growth factorsand other cytokines present in PRP normally comprise: platelet-derivedgrowth factor; transforming growth factor beta; fibroblast growth factor;insulin-like growth factor 1; insulin-like growth factor 2; vascular endothelialgrowth factor; epidermal growth factor; Interleukin 8; keratinocyte growth factor; and connective tissue growth factor.
    Presently there are two methods of PRP preparation approved by the U.S.Food and Drug Administration. Both processes involve the collection of thepatient's whole blood that is anticoagulated with citrate dextrose beforeundergoing two stages of centrifugation designed to separate the PRP aliquot from platelet-poor plasma (PPP) and red blood cells. In humans, the typical baseline blood platelet count is approximately 2oo,ooo per uL. Typically, thetherapeutic PRP concentrates the platelets by roughly five-fold. There is,however, broad variability in the production of PRP by various concentrating equipment and techniques.
    SUMMARY The present inventor has identified a number of problems of the prior art PRP preparation systems.
    The first problem of the prior art systems is that blood is taken / collectedfrom the patient with a syringe. The inventor has realized that the vacuumpressure in the syringe causes damage to the platelets” sensitive membrane,which decreases the effectiveness of the resulting PRP. Therefore, it is beneficial to use a blood bag for the collection of blood instead of a syringe.
    A second problem of the prior art systems are that they are “open” and thusexposed to the risk of infectious contamination. To improve sterility, it is preferred to have a closed system.
    A third problem of the prior art is that a substantial portion of the plateletsare damaged by contact with the hard walls of the tubes duringcentrifugation. This problem is avoided by the using bags instead of tubes in the centrifugation.
    A fourth problem of the prior art is that high volumes of blood cannot be taken from anaemic patients or patients having large burn wounds.
    The problems of the prior art has been addressed by the inventor and as afirst aspect of the present disclosure, there is provided a medical devicecomprising a first blood bag for collection of whole blood from a patient and asecond blood bag for separation of a platelet rich plasma (PRP) fraction,wherein: a whole blood inlet is provided at a first end of the first blood bag and afirst blood bag outlet is provided at a second end of the first blood bag; a packed cells outlet and a plasma outlet are connected to the first bloodbag outlet; a first flexible plastic tube connects the plasma outlet to a plasma inletprovided at a first end of the second blood bag; a second blood bag outlet is provided at a second end of the second blood bag.
    In an alternative (less preferred) configuration of the first aspect, there is nota packed cells outlet and a plasma outlet, but only the first blood bag outletconnected to the plasma inlet of the second blood bag by the first flexibletube.
    Packed cells recovered from the packed cells outlet can be reinj ected in theblood stream of a critically ill patient and thus allow for taking higher volumes of blood from the critically ill patient.
    In one embodiment, the packed cells outlet comprises a breakable lock. Sucha lock stops flow though the packed cells outlet and prevents contaminationuntil it has been broken. When the medical device is used as intended, thebreakable lock of the packed cells outlet is not broken when the plasma istransferred to the second blood bag. It is only broken when reinfusion of packed cells is needed.
    A first branching may be connected to the first blood bag outlet. In such case, the first branching comprises the packed cells outlet and the plasma outlet.
    The volume of the plasma (containing platelets) transferred to the second bagis typically about half of the volume of the whole blood provided in the firstbag. Accordingly, the volume of the first blood bag may be higher than the volume of the second blood bag.
    In one embodiment, the first flexible plastic tube comprises a breakable lock.Such a lock stops flow though the first flexible plastic tube until it has been broken.
    Preferably, a platelet-rich plasma (RPR) outlet and a platelet-poor plasma(PPP) outlet are connected to the second blood bag outlet.
    PPP recovered from the PPP outlet may be injected to the skin formoisturizing purposes. It may also be used in a moisturizing crème.Preferably, calcium and eucerin is added to the PPP for such a crème application.
    Alternatively, PPP recovered from the PPP outlet may be used in an crème orointment for topical treatment of a burn wound. Preferably, calcium andeucerin is added to the PPP for such an application. Accordingly, the medicaldevice enables the provision of packed cells, PRP and PPP, which can all beused for the treatment of a patient having a burn wound. The medical device is particularly beneficial when the burn wound is large.
    In one embodiment, the platelet-rich plasma (RPR) outlet comprises abreakable lock. Such a lock stops flow though the PRP outlet and preventscontamination until it has been broken. When the medical device is used asintended, the breakable lock of the RPR outlet is not broken until shortlybefore the PRP fraction is recovered from the second blood bag. For example,the lock in question is intended to be unbroken when the PPP fraction istransferred through the PPP outlet.
    Preferably, the device further comprises a third blood bag for collection ofplatelet-poor plasma (PPP). In such case, a second flexible plastic tube mayconnect the PPP outlet to a PPP inlet provided at a first end of the third bloodbag. Further, the third blood bag may comprise an outlet, for exampleprovided at a second end of the third blood bag, for recovery of PPP from the third bag. Such an outlet may comprise a breakable lock.
    In one embodiment, the second flexible plastic tube comprises a breakablelock. Such a lock stops flow though the second flexible plastic tube until it has been broken.
    The medical device may comprise a second branching that is connected to thesecond blood bag outlet. In such case, the second branching comprises thePRP outlet and the PPP outlet.
    The walls of the first blood bag, the second blood bag and (if present) thethird blood bag are preferably composed of a flexible plastic material according to blood bag standards.
    The first blood bag may comprise a first bag extension extending from thewalls of the first blood bag. Such an extension enables fixation of the firstblood bag during centrifugation. For example, holes penetrable by pins on acentrifuge may be provided in the first bag extension to allow the first bloodbag to be fixed, preferably in an extended (non-creased) configuration, during centrifugation.
    Likewise, the second blood bag may comprise a second bag extensionextending from the walls of the second blood bag. Such an extension enablesfixation of the second blood bag during centrifugation. For example, holespenetrable by pins on a centrifuge may be provided in the second bagextension to allow the second blood bag to be fixed, preferably in an extended (non-creased) configuration, during centrifugation.
    To reduce the impact on the platelets and to facilitate the separation ofplatelets from packed cells, the second end of the first blood bag may befunnel-shaped. Alternatively, corners of the second end of the first blood bagmay be rounded. However, a funnel shape is more preferred for the firstblood bag.
    To reduce the impact on the platelets and to facilitate the separation ofplatelets from (platelet poor) plasma, corners of the second end of the secondblood bag may be rounded, e.g. such that the bottom end of the second bloodbag has the shape of a half sphere. Alternatively, the second end of the secondblood bag may be funnel-shaped.
    As a second aspect of the present disclosure, there is provided a use of amedical device according to the first aspect for separation of platelet-rich plasma (RPR) fraction from whole blood.
    As a third aspect of the present disclosure, there is provided a method ofpreparing a platelet-rich plasma (PRP) fraction using the medical device according to the first aspect.
    The method comprises the steps of: a) subjecting the first blood bag containing whole blood to a firstcentrifugation to separate packed cells (primarily RBC) from plasma(containing platelets); b) transferring plasma (containing platelets) from the first blood bag throughthe first flexible tube (107) to the second blood bag; c) subjecting the second blood bag containing plasma (containing platelets)to a second centrifugation to settle platelets; and d) removing a platelet poor plasma (PPP) fraction from the second blood bagto obtain the PRP fraction in the second blood bag.
    The platelet count of the PRP fraction is typically 3-8 times higher than thatof the whole blood.
    Step b) may further comprise recovering of a packed cells fraction from thefirst blood bag after the plasma has been transferred to the second bag. Atleast part of such a packed cells fraction can be reinjected into thebloodstream of a patient, such as a critically ill or an anaemic patient, which preferably is the patient from which the whole blood was taken.
    The removal of the PPP fraction of step d) may be transferring the PPPfraction to the third blood bag. Uses of the PPP fraction are discussed above and below.
    The whole blood of step a) is preferably mixed with an anticoagulant, such asCPDA1.
    The first centrifugation can for example be carried out for a time period of 5-40 minutes at 500-3000 rpm. Preferably, the time period is 10-30 minutes at 750-1800 rpm.
    The second centrifugation can for example be carried out for a time period of1-10 minutes at 1500-4000 rpm. Preferably, the time period is 2-8 minutes 2000-3500 rpm.
    During the first and the second centrifugation, the first and second blood bag,respectively, are preferably fixed in an extended configuration. In theextended configuration, the walls of the blood bag in question are not creasedto any substantial degree. Pins provided on the centrifuge used for the firstand second centrifugations matching holes in extensions from the walls of the blood bags may provide such a fixation.
    The method may further comprise taking whole blood from a subject using aneedle connected to the whole blood inlet to obtain the first blood bagcontaining whole blood of step a) and administration of at least part of the PRP fraction obtained in step d) to the subject.
    Such a method comprising the taking of whole blood and administration ofPRP may be therapeutic or non-therapeutic. An example of a non-therapeutic method is a cosmetic method.
    The administration method may for example be spraying, which isparticularly beneficial in the treatment of large burn wounds (e.g. > 0.2 m2)where it is necessary to cover a large area with a limited amount of available PRP. Spraying is further discussed below with reference to Fig 3.
    The present disclosure thus provides the concept of treating a patient havinga burn wound by spraying PRP onto the burn wound. The PRP for thisconcept can be any type of PRP, but it is preferably PRP prepared according to the present disclosure.
    As a fourth aspect of the present disclosure, there is provided a kit-of-partscomprising the medical device according to the first aspect and a centrifuge.The centrifuge may be provided with pins capable of fixing a blood bag in an extended configuration during centrifugation.
    BRIEF DESCRIPTION OF THE DRAWINGS The invention is now described, by way of example, with reference to the accompanying drawings, in which: Fig 1 shows an embodiment of the system/ medical device of the present disclosure.
    Fig 2 shows a folded configuration of the medical device of Fig 1.
    Fig 3 show administration of PRP to a burn wound by means of spraying.
    DETAILED DESCRIPTION Non-limiting examples of embodiments of the system and the method of the present disclosure are described below.
    The exemplary system is a three-bag system 100. The three-bag system may also be referred to as a medical device.
    A first bag 101 of the three-bag system 100 is a blood bag for collection ofwhole blood from a patient. The walls of the first bag 101 are composed of aflexible plastic material according to blood bag standards. The first bag 101further comprises a first bag extension 101a extending from the walls of thefirst bag 101. In the first bag extension 101a, holes 101b are provided to allowthe first bag 101 to be fixed in an extended configuration duringcentrifugation. A whole blood inlet 102 is arranged at a first end 101i of thefirst bag 101 and a blood bag outlet 103 is arranged at a second end of the firstblood bag 101. To reduce the impact on the platelets and to improve theseparation of platelets from packed cells, the second end of the first bag 101 is funnel-shaped.
    A first branching 104 is connected to the blood bag outlet 103. The firstbranching 104 comprises a packed cells outlet 105 and a plasma outlet 106(for plasma containing platelets). The packed cells outlet 105 comprises abreakable lock 105a that i.a. prevents contamination. A first flexible plastictube 107 connects the plasma outlet 106 to a plasma inlet 108 arranged at afirst end 109i of a second bag 109. The walls of the second bag 109 arecomposed of a flexible plastic material according to blood bag standards. Thesecond bag 109 further comprises a second bag extension 109a extendingfrom the walls of the second bag 109. In the second bag extension 109a, holes109b are provided to allow the second bag 109 to be fixed in an extendedconfiguration during centrifugation. An outlet 111 is arranged at a second endof the second bag 109. To reduce the impact on the platelets and to improvethe separation of platelets from (platelet poor) plasma, the corners 109c ofthe second end of the second bag 109 are rounded, e.g. such that the bottomend of the second bag 109 has the shape of a half sphere. The first flexibleplastic tube 107 comprises a breakable lock 107a. Further, a first clamp 110 isarranged on the first flexible plastic tube 107 such that flow through the firstflexible plastic tube 107 can be stopped also after the breakable lock 107a hasbeen broken. The first clamp 110 may be arranged upstream the breakable lock 107a.
    A second branching 112 is connected to the outlet 111 of the second bag 109.The second branching 112 comprises a platelet-rich plasma (RPR) outlet 113and a platelet-poor plasma (PPP) outlet 114. The PRP outlet 113 comprises abreakable lock 113a that i.a. prevents contamination. A second flexible plastictube 115 connects the PPP outlet 114 to a PPP inlet 116 arranged at a first end118i of a third bag 118 for collection of PPP. The walls of the third bag 118 arecomposed of a flexible plastic material according to blood bag standards. Thesecond flexible plastic tube 115 comprises a breakable lock 115a. Further, asecond clamp 117 is arranged on the second flexible plastic tube 115 such that flow through the second flexible plastic tube 115 can be stopped also after the breakable lock 115a has been broken. The second clamp 117, may be arranged upstream the breakable lock 115a.
    In the method, whole blood is first collected from a patient in the first bag 101(i.e. the blood bag). A clamp 120 is then used to prevent blood from leakingthrough the whole blood inlet 102 of the first bag 101. The collected volume ofwhole blood may for example be about 100 ml. In the first bag 101, the wholeblood is mixed with an anticoagulant, preferably CPDA1. The collection andmixing with the anticoagulant are well known to the skilled person. The firstbag 101 containing the whole blood mixed with the anticoagulant is thensubjected to a first centrifugation, e.g. for 18 minutes at 1100 rpm, forseparation of red blood cells (RBC) from plasma (containing platelets).During centrifugation, pins of the centrifuge penetrate the holes 101b of thefirst bag extension 101a to fix the first bag 101 in an extended configuration(compaction of the bag is thus avoided). The orientation of the first bag 101during the first centrifugation is such that a packed cells fraction is formed at the first end 101i of the first bag 101.
    After the first centrifugation, the breakable lock 107a of the first flexible tube107 is broke open and the first bag is gently squeezed such that thesupernatant, i.e. the platelet-containing plasma, is gently pushed through theplasma outlet 106 and the first flexible tube 107 to the second bag 109. Then,the flow through the first flexible tube 107 is stopped by the first clamp 110.The packed cells fraction remains in the first bag and can be obtainedthrough the packed cells outlet 105 after that the breakable lock 105a hasbeen broke open. The packed cells fraction may be reinjected into the bloodstream of the patient, in particular when the patients is anaemic or has large burn wounds.
    The concentration of platelets in the plasma transferred to the second bag109 is typically about 1.5 higher than in the whole blood. That means that ifthe platelet count in the whole blood was 200000 per ul, it is typically 300000 per ul in the plasma. If the original volume of whole blood was 100 11 ml, the volume of plasma transported to the second bag 109 is typically about50 ml (which means that about 25% of the platelets could not be separatedfrom the packed cells if the platelet concentration 1.5 times higher in theseparated plasma than in the whole blood). To further increase the plateletcount, the second bag 109 containing the plasma is subjected to a secondcentrifugation, e.g. for 4 minutes at 2700 rpm. During the secondcentrifugation, the orientation of the second bag is such that platelets settle atthe first end 109i of the second bag 109 (the first end 109i is the end by theinlet 108 of the second bag 109). During centrifugation, pins of the centrifugepenetrate the holes 109b of the second bag extension 109a to fix the secondbag 109 in an extended configuration. After the second centrifugation, thesecond bag is rested, e.g. for 30-90 minutes to allow expansion of the settled platelets.
    The breakable lock 115a of the second flexible tube 115 is then broke open andthe second bag 109 is squeezed such that the supernatant, i.e. the platelet-poor plasma (PPP), is pushed through the PPP outlet 106 and the secondflexible tube 107 to the third bag 118. The PPP collected in the third bag 118 may for example be used as a skin moisturizer.
    Then, the flow through the second flexible tube 115 is stopped by the secondclamp 117 and a plasma fraction containing the expanded platelets settled atthe first end 109i of the second bag 109, i.e. the platelet-rich plasma (PRP), isrecovered through the PRP outlet 113 by gently squeezing the second bag 109after the breakable lock 113a of the PRP outlet has been broke open. Theplatelet count of the PRP fraction is typically 3-8 times higher than that of thewhole blood.
    Figure 2 shows a folded configuration of the medical device of Figure 2 thatcan be used during the centrifugations. Pins 201 penetrate holes 101b, 109b,118b made in the extensions 101a, 109a, 118a from the walls of the bags 101,109, 118. Thereby, the bags 101, 109, 118 are fixed in extended configurations during the centrifugations. During the first centrifugation, the folded 12 configuration preferably has the orientation shown in Figure 2 such thatpacked cells are formed (settle) at the first end 101i of the first bag 101.During the second centrifugation, the folded configuration of figure 2 ispreferably turned upside-down such that platelets settle at the first end 109iof the second bag 109.
    Figure 3 shows a spraying device 300 by means of which PRP is sprayed ontoa large burn wound 301. The spaying device 300 preferably composed of suchmaterial(s) that it can be sterilized by autoclaving. An example of such a material is metal, preferably stainless steel.
    The invention has mainly been described above with reference to a fewembodiments. However, as is readily appreciated by a person skilled in theart, other embodiments than the ones disclosed above are equally possible within the scope of the invention, as defined by the appended patent claims.
    权利要求:
    Claims (11)
    [1] 1. A medical device (100) comprising a first blood bag (101) for collectionof whole blood from a patient and a second blood bag (109) for separation ofa platelet rich plasma (PRP) fraction, wherein: a whole blood inlet (102) is provided at a first end (101i) of the first bloodbag (101) and a first blood bag outlet (103) is provided at a second end of thefirst blood bag (101); a packed cells outlet (105) and a plasma outlet (106) are connected to thefirst blood bag outlet (103); a first flexible plastic tube (107) connects the plasma outlet (106) to aplasma inlet (108) provided at a first end (109i) of the second blood bag(109): a second blood bag outlet (111) is provided at a second end of the secondblood bag (109) wherein a first branching (104) is connected to the first blood bag outlet(103), which first branching (104) comprises the packed cells outlet (105) andthe plasma outlet (106).
    [2] 2. The medical device of claim 1, wherein the packed cells outlet (105) comprises a breakable lock (105a).
    [3] 3. The medical device of any one of claim 1-2, wherein the volume of the first blood bag (101) is higher than the volume of the second blood bag (109).
    [4] 4. The medical device of any one of claims 1-3, wherein the first flexible plastic tube (107) comprises a breakable lock (107a).
    [5] 5. The medical device of any one of claims 1-4, wherein a platelet-richplasma (RPR) outlet (113) and a platelet-poor plasma (PPP) outlet (114) are connected to the second blood bag outlet (111).
    [6] 6. The medical device of claim 5, wherein the platelet-rich plasma (RPR) outlet (113) comprises a breakable lock (113a).
    [7] 7. The medical device of any one of claims 5-6, further comprising a thirdblood bag (118) for collection of platelet-poor plasma (PPP) and wherein asecond flexible plastic tube (115) connects the PPP outlet (114) to a PPP inlet(116) provided at a first end (118i) of the third blood bag (118).
    [8] 8. The medical device of claim 7, wherein the second flexible plastic tube (115) comprises a breakable lock (115a)
    [9] 9. The medical device of anyone of claims 5-8, wherein a second branching(112) is connected to the second blood bag outlet (111), which second branching (111) comprises the PRP outlet (113) and the PPP outlet (114).
    [10] 10. Use ex vivo of a medical device according to any one of the precedingclaims for separation of platelet-rich plasma (PRP) fraction from wholeblood.
    [11] 11. Method of preparing a platelet-rich plasma (PRP) fraction using themedical device (100) according to any one of claims 1-9, comprising the stepsof: a) subjecting the first blood bag (101) containing whole blood to a firstcentrifugation to separate packed cells from plasma; b) transferring plasma from the first blood bag (101) through the first flexibletube (107) to the second blood bag (109); c) subjecting the second blood bag (109) containing plasma to a secondcentrifugation to settle platelets; and d) removing a platelet poor plasma (PPP) fraction from the second blood bag to obtain the PRP fraction in the second blood bag (109).
    类似技术:
    公开号 | 公开日 | 专利标题
    KR102362722B1|2022-02-14|New standardizations & medical devices for the preparation of platelet rich plasma| or bone marrow centrate| alone or in combination with hyaluronic acid
    EA014435B1|2010-12-30|Conditioned blood composition and method for its production
    US20150209502A1|2015-07-30|Triple syringe and methods of making platelet-enriched plasma and use thereof
    SE1650038A1|2017-07-15|Method, device and kit for the preparation of prp
    WO2017000851A1|2017-01-05|Integrated autologous platelet-rich gel preparation kit
    Cieślik-Bielecka et al.2016|Benefit of leukocyte-and platelet-rich plasma in operative wound closure in oral and maxillofacial surgery
    EP2976098B1|2018-08-22|Implantable serum-globin preparations for regeneration of tissues and treatment of wounds
    de Souza et al.2003|Antenatal erythropoietin and intra-operative cell salvage in a Jehovah's Witness with placenta praevia
    US20200164121A1|2020-05-28|Method, device and kit for the preparation of prp
    Crescibene et al.2015|Postoperative autologous reinfusion in total knee replacement
    JP6999927B2|2022-01-19|How to make platelet-rich plasma
    RU2710367C2|2019-12-26|Method for producing cytokines from umbilical blood thrombocytes as substrate for developing drugs for humans and animals
    JP2019517566A|2019-06-24|System and method for treating wounds using wound packing
    CN102940657A|2013-02-27|Medicine composition for treating cardia-cerebrovascular diseases
    WO2019220175A1|2019-11-21|Preperation kit by blood bag with capability of centrifuge in one stage
    TW202026416A|2020-07-16|Blood separation method
    TWM605103U|2020-12-11|Apparatus and kit for producing platelet rich plasma and platelet rich fibrin
    CN102940669B|2014-05-14|Medicine composition for treating cardia-cerebrovascular diseases
    TW202126316A|2021-07-16|Method of preparing platelet lysate and use thereof for treating vocal cord disease
    RU2743227C1|2021-02-16|A method of obtaining a complex of allogeneic lyophilized platelet growth factors for stimulating regenerative osteogenesis
    TW202126315A|2021-07-16|Method of preparing platelet lysate and use thereof for improving female pregnancy success rate
    Hasan et al.2020|Platelet rich plasma | treatment: A view
    CN206366057U|2017-08-01|A kind of blood purification system
    Viebahn-Haensler2005|Milestones of medical ozone
    CN109045383A|2018-12-21|A kind of diacan
    同族专利:
    公开号 | 公开日
    SE540289C2|2018-05-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2019016577A1|2017-07-18|2019-01-24|Ghanbari Ahmad|Method, device and kit for the preparation of prp|
    CN110944616A|2017-07-22|2020-03-31|艾哈迈德·甘巴里|PRP production kit with the ability to separate PRP from blood and then infuse the remaining elements|
    法律状态:
    2021-08-31| NUG| Patent has lapsed|
    优先权:
    申请号 | 申请日 | 专利标题
    SE1650038A|SE540289C2|2016-01-14|2016-01-14|Method, device and kit for the preparation of prp|SE1650038A| SE540289C2|2016-01-14|2016-01-14|Method, device and kit for the preparation of prp|
    [返回顶部]